{"id":237733,"date":"2021-04-19T17:54:07","date_gmt":"2021-04-19T21:54:07","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=237733"},"modified":"2021-04-19T17:55:37","modified_gmt":"2021-04-19T21:55:37","slug":"vaccines-soberana-02-to-be-tested-on-24000-people-in-iran","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/coronavirus\/vaccines-soberana-02-to-be-tested-on-24000-people-in-iran\/","title":{"rendered":"Vaccines: Soberana 02 to be tested on 24,000 people in Iran"},"content":{"rendered":"

Iran<\/span><\/a> will begin in the coming days the third phase of the clinical trial of the <\/span>Cuban Soberana 02 vaccine<\/span><\/a>, locally called Pasteur, which will involve 24,000 volunteers from seven provinces in the north, center and south of the country.<\/span><\/p>\n

The director of the Pasteur Institute of Iran, Alireza Biglar\u00ed, explained this Monday that eight Universities of Medical Sciences of Mazandaran, Babol, Isfahan, Yazd, Kerman, Hormozgan, Zanyan and Hamedan are participating in the trials.<\/span><\/p>\n

https:\/\/twitter.com\/ONU_Cuba\/status\/1383082381544976394?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1383082381544976394%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Foncubanews.com%2Fcuba%2Fvacunas-soberana-02-se-probara-en-24-000-personas-en-iran%2F<\/p>\n

In two of the provinces a booster dose will be administered, in addition to the two doses of the vaccine, according to Biglar\u00ed, quoted by local ISNA news agency.<\/span><\/p>\n

\u201cThe booster dose can be effective in boosting the immunity of people who have previously been infected with COVID-19,\u201d he explained.<\/span><\/p>\n

Biglar\u00ed announced that after the final stage of the clinical trial and if it is successful, this serum will be able to be used in the general vaccination in the country, which so far accounts for more than 66,000 deaths and 2.2 million infections and which has a very limited number of doses.<\/span><\/p>\n

According to the agreement signed last January between the Finlay Vaccine Institute (IFV) of Havana and the Pasteur Institute, the third and last phase of the Soberana 02 trials is also being carried out in the Persian country and then the technology is transferred to produce the drug locally.<\/span><\/p>\n

This candidate began the final stage of clinical trials in Havana on March 8 with 44,010 volunteers, and at the end of the month the tests were expanded with a parallel intervention study of another 150,000 people.<\/span><\/p>\n

Cuba sends 100,000 doses of the Soberana 02 vaccine candidate to Iran<\/a><\/p><\/blockquote>\n